120 related articles for article (PubMed ID: 10099920)
1. International economic analysis of primary prevention of cardiovascular disease with pravastatin in WOSCOPS. West of Scotland Coronary Prevention Study.
Caro J; Klittich W; McGuire A; Ford I; Pettitt D; Norrie J; Shepherd J
Eur Heart J; 1999 Feb; 20(4):263-8. PubMed ID: 10099920
[TBL] [Abstract][Full Text] [Related]
2. Are the WOSCOPS clinical and economic findings generalizable to other populations? A case study for Belgium. The WOSCOPS Economic Analysis Group. West of Scotland Coronary Prevention Study.
Caro JJ; Huybrechts KF; De Backer G; De Bacquer D; Closon MC
Acta Cardiol; 2000 Aug; 55(4):239-46. PubMed ID: 11041122
[TBL] [Abstract][Full Text] [Related]
3. The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin.
Caro J; Klittich W; McGuire A; Ford I; Norrie J; Pettitt D; McMurray J; Shepherd J
BMJ; 1997 Dec; 315(7122):1577-82. PubMed ID: 9437275
[TBL] [Abstract][Full Text] [Related]
4. Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study.
McConnachie A; Walker A; Robertson M; Marchbank L; Peacock J; Packard CJ; Cobbe SM; Ford I
Eur Heart J; 2014 Feb; 35(5):290-8. PubMed ID: 23839541
[TBL] [Abstract][Full Text] [Related]
5. A comparison of economic modelling and clinical trials in the economic evaluation of cholesterol-modifying pharmacotherapy.
Morris S
Health Econ; 1997; 6(6):589-601. PubMed ID: 9466141
[TBL] [Abstract][Full Text] [Related]
6. Cost effectiveness of coronary prevention.
Szucs TD; März W
Eur Heart J; 1999 Feb; 20(4):317-8. PubMed ID: 10099929
[No Abstract] [Full Text] [Related]
7. Cost-effectiveness of pravastatin for primary prevention of coronary artery disease in Japan.
Nagata-Kobayashi S; Shimbo T; Matsui K; Fukui T
Int J Cardiol; 2005 Sep; 104(2):213-23. PubMed ID: 16168816
[TBL] [Abstract][Full Text] [Related]
8. Pravastatin. A pharmacoeconomic review of its use in primary and secondary prevention of coronary heart disease.
Coukell AJ; Wilde MI
Pharmacoeconomics; 1998 Aug; 14(2):217-36. PubMed ID: 10186462
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of pravastatin in secondary prevention of coronary heart disease: comparison between Belgium and the United States of a projected risk model.
Muls E; Van Ganse E; Closon MC
Atherosclerosis; 1998 Apr; 137 Suppl():S111-6. PubMed ID: 9694550
[TBL] [Abstract][Full Text] [Related]
10. West of Scotland Coronary Prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials.
Lancet; 1996 Nov; 348(9038):1339-42. PubMed ID: 8918276
[TBL] [Abstract][Full Text] [Related]
11. Allocating funds for cardiovascular disease prevention in light of the NCEP ATP III guidelines.
Caro J; Huybrechts KF; Klittich WS; Jackson JD; McGuire A;
Am J Manag Care; 2003 Jul; 9(7):477-89. PubMed ID: 12866627
[TBL] [Abstract][Full Text] [Related]
12. Preventing coronary artery disease in the West of Scotland: implications for primary prevention.
Shepherd J
Am J Cardiol; 1998 Nov; 82(10B):57T-59T. PubMed ID: 9860377
[TBL] [Abstract][Full Text] [Related]
13. Measuring the cost-effectiveness of lipid-lowering drugs in the elderly: the outcomes research and economic analysis components of the PROSPER trial.
Avorn J; Benner J; Ford I; Ganz DA; Gaw A; Glynn RJ; Jackson J; Lagaay AM; Schneeweiss S; Walley T; Wang PS;
Control Clin Trials; 2002 Dec; 23(6):757-73. PubMed ID: 12505250
[TBL] [Abstract][Full Text] [Related]
14. Blood rheology, cardiovascular risk factors, and cardiovascular disease: the West of Scotland Coronary Prevention Study.
Lowe G; Rumley A; Norrie J; Ford I; Shepherd J; Cobbe S; Macfarlane P; Packard C
Thromb Haemost; 2000 Oct; 84(4):553-8. PubMed ID: 11057849
[TBL] [Abstract][Full Text] [Related]
15. The cardiovascular event reduction tool (CERT)--a simplified cardiac risk prediction model developed from the West of Scotland Coronary Prevention Study (WOSCOPS).
L'Italien G; Ford I; Norrie J; LaPuerta P; Ehreth J; Jackson J; Shepherd J
Am J Cardiol; 2000 Mar; 85(6):720-4. PubMed ID: 12000046
[TBL] [Abstract][Full Text] [Related]
16. [Pharmacoeconomic evaluation of pravastatin in coronary secondary prevention in patients with myocardial infarct or unstable angina pectoris. An analysis based on the LIPID Study].
Szucs TD; Bertel O; Darioli R; Gutzwiller F; Mordasini R
Praxis (Bern 1994); 2000 Apr; 89(18):745-52. PubMed ID: 10823012
[TBL] [Abstract][Full Text] [Related]
17. [Economic aspects of drug therapy exemplified by pravastatin. A socioeconomic analysis of cholesterol synthase enzyme inhibition in coronary heart disease patients].
Berger K; Klose G; Szucs TD
Med Klin (Munich); 1997 Jun; 92(6):363-9. PubMed ID: 9297070
[TBL] [Abstract][Full Text] [Related]
18. [Socioeconomic aspects of therapy of cardiovascular diseases].
Lauterbach KW
Herz; 2000 Aug; 25(5):473-5. PubMed ID: 10992995
[No Abstract] [Full Text] [Related]
19. Pravastatin for Primary Prevention in Older Adults: Restricted Mean Survival Time Analysis.
Orkaby AR; Rich MW; Sun R; Lux E; Wei LJ; Kim DH
J Am Geriatr Soc; 2018 Oct; 66(10):1987-1991. PubMed ID: 30251369
[TBL] [Abstract][Full Text] [Related]
20. The effect of low-dose pravastatin in metabolic syndrome for primary prevention of cardiovascular disease in Japan: a post hoc analysis of the MEGA study.
Matsushima T; Nakaya N; Mizuno K; Ohashi Y; Teramoto T; Yokoyama S; Ichikawa S; Ishikura N; Kamiyama K; Nakamura H;
J Cardiovasc Pharmacol Ther; 2012 Jun; 17(2):153-8. PubMed ID: 22573644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
